Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 1;18(1):87-91.
doi: 10.22034/APJCP.2017.18.1.87.

General Characteristics and Cytotoxic Effects of Nano-Poly (Butyl Cyanoacrylate) Containing Carboplatin on Ovarian Cancer Cells

Affiliations

General Characteristics and Cytotoxic Effects of Nano-Poly (Butyl Cyanoacrylate) Containing Carboplatin on Ovarian Cancer Cells

Leila Kanaani et al. Asian Pac J Cancer Prev. .

Abstract

The initial response to treatment and subsequent development of resistance to carboplatin are very important challenges. Use of nano drug delivery is a new method to replace standard chemotherapy. In this research, both non-PEGylated and PEGylated nanoparticles (NPs) were prepared by mini-emulsion polymerization of poly (butyl cyanoacrylate) (PBCA) NPs. Characteristics such as size, polydispersity index (PDI), zeta potential, drug release, and stability were examined. In addition, infrared spectroscopy was used for description of the produced NPs. Then, cytotoxicity effects of both formulations were studied on the A2780CIS ovarian cancer cell line with incubation for 24, 48, and 72h. Examination of characteristics of loaded carboplatin on the PBCA NPs under suitable laboratory conditions showed a positive effect of PEG on their properties. Cytotoxicity studies demonstrated greater toxicity with both formulations of nano-drugs than the free drug. The results indicated that PBCA NPs can be considered as suitable candidates for nano-drugs in chemotherapy.

Keywords: Ovarian cancer; carboplatin; poly (butyl Cyanoacrylate) nanoparticle; nano-drug delivery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anionic Polymerization of Alkyl Cyanoacrylate Monomers Leading to the Formation of the Nanoparticles. The Hydroxyl Ions in the Water Start the Reaction
Figure 2
Figure 2
Infrared Spectra of PEGylated PBCA NPs
Figure 3
Figure 3
Pattern of Carboplatin Release of PBCA NPs (Blue and Red Lines are Relevant to the PEGylated and no-PEGylated Nano Drugs, Respectively)
Figure 4
Figure 4
Cytotoxicity Effects of Free Carboplatin and Loaded Carboplatin on the PBCA NPs in the A2780CIS Cell after 24h Incubation. (a) PEGylated NPs (P<0.05) and (b) no- PEGylated NPs (P<0.05)
Figure 5
Figure 5
Cytotoxicity Effects of Free Carboplatin and Loaded Carboplatin on the PBCA NPs in the A2780CIS Cell after 48h Incubation. (a) PEGylated NPs (P<0.05) and (b) no-PEGylated NPs (P<0.05)
Figure 6
Figure 6
Cytotoxicity Effects of Free Carboplatin and Loaded Carboplatin on the PBCA NPs in the A2780CIS Cell after 72h Incubation. (a) PEGylated NPs (P<0.05) and (b) no-PEGylated NPs (P<0.05)

Similar articles

Cited by

References

    1. Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood–brain barrier. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:463–463. - PubMed
    1. Antonietti M, Landfester K. Polyreactions in miniemulsions. Prog. Polym Sci. 2002;27:689–689.
    1. Behan N, Birkinshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles:a mechanistic study of polymerisation and particle formation. Biomaterials. 2001;22:1335–1335. - PubMed
    1. Douglas S, Illum L, Davis S. Particle size and size distribution of poly (butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers. J Colloid Interface Sci. 1985;103:154–154.
    1. Douglas S, Illum L, Davis S, et al. Particle size and size distribution of poly (butyl-2-cyanoacrylate) nanoparticles:I. Influence of physicochemical factors. J Colloid Interface Sci. 1984;101:149–149.